Medizinische Klinik und Poliklinik A	Tel. (0251) 83-47587 Fax: (0251) 83-47588 e-mail: berdel@uni-muenster.de www: medweb.uni-muenster.de/institute/meda/
Albert-Schweitzer-Str. 33 48129 Münster Direktor: Prof. Dr. med. W. E. Berdel
Forschungsschwerpunkte 2003 - 2004    zurück    weiter

Arbeitsbereich Prof. Dr. W. E. Berdel Zur Rolle von Zytokinen und Molekülen der extrazellulären Matrix bei soliden Tumoren und Lymphomen   Zur Zeit werden die folgenden drei Themen experimentell und klinisch untersucht: Studien zur Expression und Produktion des endogenen Inhibitors von Metalloproteinase TIMP-1 (Tissue Inhibitor of Metalloproteinase-1) in Lymphknoten von Patienten mit Morbus Hodgkin sowie zur Funktion von TIMP-1. Untersuchungen zur Interaktion von Fibroblasten-Wachstumsfaktoren (bFGF und hKGF) mit Tumorzellen unterschiedlicher Histologie. Frühe klinische Studien mit molekular "targetierten" Substanzen. Veröffentlichungen: Bieker, R., Padro, T., Kramer, J., Steins, M., Kessler, T., Retzlaff, S., Herrera, F., Kienast, J., Berdel, W. E. and Mesters, R. M.: Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res, 63: 7241-7246, 2003. Bieker, R., Lerchenmüller, C., Wehmeyer, J., Serve, H. L., Mesters, R. M., Büchner, T. and Berdel, W. E.: Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia. Oncol Rep, 10: 915-920, 2003. Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padro, T., Kropff, M., Scheffold, C., Kroger, M., Mesters, R. M., Berdel, W. E. and Kienast, J.: Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood, 101: 2775-2783, 2003. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P., Duhrsen, U., Flasshove, M., Ottmann, O. G., Jung, W., Cavalli, F., Kuse, R., Thomalla, J., Serve, H., O'Farrell, A. M., Jacobs, M., Brega, N. M., Scigalla, P., Hossfeld, D. K. and Berdel, W. E.: A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 102: 2763-2767, 2003. O'Farrell, A. M., Foran, J. M., Fiedler, W., Serve, H., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., Heinrich, M. C., Berdel, W. E., Bello, C., Jacobs, M., Scigalla, P., Manning, W. C., Kelsey, S. and Cherrington, J. M.: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res, 9: 5465-5476, 2003. Oelmann, E., Haghgu, S., Kulimova, E., Serve, H., Schmitmann, C. and Berdel, W. E.: Re Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst, 95: 1171-1173; author reply 1173-1174, 2003. Schmoll, H. J., Kollmannsberger, C., Metzner, B., Hartmann, J. T., Schleucher, N., Schoffski, P., Schleicher, J., Rick, O., Beyer, J., Hossfeld, D., Kanz, L., Berdel, W. E., Andreesen, R. and Bokemeyer, C.: Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol, 21: 4083-4091, 2003. Steins, M. B., Bieker, R., Padro, T., Kessler, T., Kienast, J., Berdel, W. E. and Mesters, R. M.: Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma, 44: 1489-1493, 2003. Kienast, J. and Berdel, W. E.: c-maf in multiple myeloma: an oncogene enhancing tumor-stroma interactions. Cancer Cell, 5: 109-110, 2004. Oelmann, E., Haghgu, S., Kulimova, E., Mesters, R. M., Kienast, J., Herbst, H., Schmitmann, C., Kolkmeyer, A., Serve, H. and Berdel, W. E.: Influence of keratinocyte growth factor on clonal growth of epithelial tumor cells, lymphoma and leukemia cells and on sensitivity of tumor cells towards 5-fluorouracil in vitro. Int J Oncol, 25: 1001-1012, 2004. Reinmuth, N., Mesters, R. M., Bieker, R., Hoffknecht, P., Berdel, W. E. and Thomas, M.: Signal transduction pathways as novel therapy targets in lung cancer. Lung Cancer, 45 Suppl 2: S177-186, 2004. Barczyk, K., Kreuter, M., Pryjma, J., Booy, E. P., Maddika, S., Ghavami, S., Berdel, W. E., Roth, J. and Los, M.: Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy. Int J Cancer 216: 167-173, 2005. Fiedler, W., Serve, H., Dohner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A. M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., Louie, S. G., Hong, W., Brega, N. M., Massimini, G., Scigalla, P., Berdel, W. E. and Hossfeld, D. K.: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood, 105: 986-993, 2005. Josting, A., Rudolph, C., Mapara, M., Glossmann, J. P., Sienawski, M., Sieber, M., Kirchner, H. H.,Dorken, B., Hossfeld, D. K., Kisro, J., Metzner, B., Berdel, W. E., Diehl, V. and Engert, A.: Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol, 16: 116-123, 2005. Werkmeister, R., Fillies, T., Gaertner, C., Joos, U., and Berdel, W. E.: A clinical phase I/II trial of rhIL-4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity. Oncol Rep, 13: 449-452, 2005